| References |
|
|
Alton EWFW,
Middleton PG,
Caplen NJ et al.
(1993)
Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice.
Nature Genetics
5:
135–142.
|
|
|
Alton EWFW,
Stern M,
Farley R et al.
(1999)
Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.
Lancet
353:
947–954.
|
|
|
Anderson DG,
Akinc A,
Hossain N and
Langer R
(2005)
Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters).
Molecular Therapy
11:
426–434.
|
|
|
Coates CJ,
Kaminski JM,
Summers JB et al.
(2005)
Site-directed genome modification: derivatives of DNA-modifying enzymes as targeting tools.
Trends in Biotechnology
23:
407–419.
|
|
|
Dykxhoorn DM,
Novina CD and
Sharp PA
(2003)
Killing the messenger: short RNAs that silence gene expression.
Nature Reviews. Molecular Cell Biology
4:
457–467.
|
|
|
Fellowes R,
Etheridge CJ,
Coade S et al.
(2000)
Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery.
Gene Therapy
7:
967–977.
|
|
|
Ferber D
(2001)
Gene therapy. Safer and virus-free?
Science
294:
1638–1642.
|
|
|
Jenke AC,
Eisenberger T,
Baiker A et al.
(2005)
The nonviral episomal replicating vector pEPI-1 allows long-term inhibition of bcr-abl expression by shRNA.
Human Gene Therapy
16:
533–539.
|
|
|
Kaushik A
(2001)
Leuvectin vical inc.
Current Opinion in Investigational Drugs
2:
976–981.
|
|
|
Kolb AF,
Coates CJ,
Kaminski JM et al.
(2005)
Site-directed genome modification: nucleic acid and protein modules for targeted integration and gene correction.
Trends in Biotechnology
23:
399–406.
|
|
|
Kostarelos K and
Miller AD
(2005)
Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors.
Chemical Society Reviews
34:
970–994.
|
|
|
Martin-Herranz A,
Ahmad A,
Evans HM et al.
(2004)
Surface functionalized cationic lipid–DNA complexes for gene delivery: PEGylated lamellar complexes exhibit distinct DNA–DNA interaction regimes.
Biophysical Journal
86:
1160–1168.
|
|
|
book
Miller AD
(1999)
"Nonviral delivery systems for gene therapy".
In: Lemoine NR (ed.)
Understanding Gene Therapy,
pp.
43–69.
Oxford: Bios Scientific Publishers.
|
|
|
Miller AD
(2003)
The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy.
Current Medicinal Chemistry
10:
1195–1211.
|
|
|
Morrissey DV,
Lockridge JA,
Shaw L et al.
(2005)
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.
Nature Biotechnology
23:
1002–1007.
|
|
|
Naito Y,
Yamada T,
Ui-Tei K,
Morishita S and
Saigo K
(2004)
siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference.
Nucleic Acids Research
32:
W124–W129.
|
|
|
Shi N,
Boado RJ and
Pardridge WM
(2001)
Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes.
Pharmaceutical Research
18:
1091–1095.
|
|
|
Shi NY and
Pardridge WM
(2000)
Noninvasive gene targeting to the brain.
Proceedings of the National Academy of Sciences of the USA
97:
7567–7572.
|
|
|
Spagnou S,
Miller AD and
Keller M
(2004)
Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Biochemistry
43:
13348–13356.
|
|
|
Tagawa T,
Manvell M,
Brown N et al.
(2002)
Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA.
Gene Therapy
9:
564–576.
|
|
|
book
Thanou M,
Waddington S and
Miller AD
(2007)
"Gene therapy".
In: Taylor JB and
Triggle DJ (eds)
Comprehensive Medicinal Chemistry II, vol. 1,
pp.
297–319.
Oxford: Elsevier.
|
|
|
Ui-Tei K,
Naito Y,
Takahashi F et al.
(2004)
Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.
Nucleic Acids Research
32:
936–948.
|
|
|
Wheeler JJ,
Palmer L,
Ossanlou M et al.
(1999)
Stabilized plasmid–lipid particles: construction and characterization.
Gene Therapy
6:
271–281.
|
|
|
Zhang YP,
Sekirov L,
Saravolac EG et al.
(1999)
Stabilized plasmid–lipid particles for regional gene therapy: formulation and transfection properties.
Gene Therapy
6:
1438–1447.
|
|
|
Zimmermann TS,
Lee AC,
Akinc A et al.
(2006)
RNAi-mediated gene silencing in non-human primates.
Nature
441:
111–114.
|
| Further Reading |
|
|
Fletcher S,
Ahmad A,
Perouzel E et al.
(2006)
In vivo studies of dialkynoyl analogues of DOTAP demonstrate improved gene transfer efficiency of cationic liposomes in mouse lung.
Journal of Medicinal Chemistry
49:
349–357.
|
|
|
Fletcher S,
Ahmad A,
Perouzel E,
Jorgensen MR and
Miller AD
(2006)
A dialkanoyl analogue of DOPE improves gene transfer of lower-charged, cationic lipoplexes.
Organic & Biomolecular Chemistry
4:
196–199.
|
|
|
Lu C,
Tej SS,
Luo S et al.
(2005)
Elucidation of the small RNA component of the transcriptome.
Science
309:
1567–1569.
|
|
|
Mattick JS
(2005)
The functional genomics of noncoding RNA.
Science
309:
1527–1528.
|
|
|
Miller AD
(1998)
Cationic liposomes for gene therapy.
Angewandte Chemie (International ed. in English)
37:
1768–1785.
|
|
|
Wente SR
(2000)
Gatekeepers of the nucleus.
Science
288:
1374–1377.
|
